MedTrace Logo

Mixed Antagonist of Serotonin for Claudication Optimal Therapy

NCT00300339 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 599

Last updated 2008-12-19

No results posted yet for this study

Summary

To investigate in patients suffering from intermittent claudication due to Fontaine stage II PAD whether a 24-week treatment by SL650472 OD on top of clopidogrel may result in an improvement of walking capacity, by comparing three doses of SL650472 to placebo, and to calibrate such effect versus cilostazol

Conditions

  • Intermittent Claudication

Interventions

DRUG

SL650472, Clopidogrel

Sponsors & Collaborators

Principal Investigators

  • ICD CSD · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • Germany
  • Mexico
  • Russia
  • Sweden
  • Ukraine

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00300339 on ClinicalTrials.gov